Some Physiological Effects of Momordica charantia and Trigonella foenum-graecum Extracts in Diabetic Rats as Compared with Cidophage®

This study was conducted to evaluate the anti-diabetic properties of ethanolic extract of two plants commonly used in folk medicine, Mormodica charantia (bitter melon) and Trigonella foenum-graecum (fenugreek). The study was performed on STZinduced diabetic rats (DM type-I). Plant extracts of these two plants were given to STZ diabetic rats at the concentration of 500 mg/kg body weight ,50 mg/kg body weight respectively. Cidophage® (metformin HCl) were administered to another group to support the results at a dose of 500 mg/kg body weight, the ethanolic extracts and Cidophage administered orally once a day for four weeks using a stomach tube and; serum samples were obtained for biochemical analysis. The extracts caused significant decreases in glucose levels compared with diabetic control rats. Insulin secretions were increased after 4 weeks of treatment with Cidophage® compared with the control non-diabetic rats. Levels of AST and ALT liver enzymes were normalized by all treatments. Decreases in liver cholesterol, triglycerides, and LDL in diabetic rats were observed with all treatments. HDL levels were increased by the treatments in the following order: bitter melon, Cidophage®, and fenugreek. Creatinine levels were reduced by all treatments. Serum nitric oxide and malonaldehyde levels were reduced by all extracts. GSH levels were increased by all extracts. Extravasation as measured by the Evans Blue test increased significantly in STZ-induced diabetic animals. This effect was reversed by ethanolic extracts of bitter melon or fenugreek.

Authors:

• Wehash
• F. E.
• Ismail I. Abo-Ghanema
• Rasha Mohamed Saleh

Keywords:

• Cidophage®
• Diabetic rats
• Mormodica charantia
• Trigonella foenum-graecum

References:

[1] Powers A. Diabetes mellitus In: Harrison-s principles of internal
medicine (Ed Fauci A). New York: Mc Graw Hill; 2008.
[2] Nadas J, Putz Z, Fovenyi J, Gaal Z, Gyimesi A, Hidvegi T, Hosszufalusi
N, et al., (2009): Cardiovascular risk factors characteristic for the
metabolic syndrome in adult patients with type 1 diabetes. Exp Clin
Endocrinol Diabetes. 117(3):107-112.
[3] Hannan JMA, Ali L, Rokeya B, Khaleque J, Akhter M, Flatt PR, Abdel-
Wahab YHA (2007). Soluble dietary fibre fraction of Trigonella
foenum-graecum (fenugreek) seed improves glucose homeostasis in
animal models of type 1 and type 2 diabetes by delaying carbohydrate
digestion and absorption, and enhancing insulin action. Br J
Nutr.;97(3):514-521.
[4] Virdi J, Sivakami S, Shahani S, Suthar AC, Banavalikar MM and
Biyani MK (2003): Antihyperglycemic effects of three extracts from
Momordica charantia. J Ethnopharmacol 88(1): 107-111.
[5] Elsner M, Guldbakke B, Tiedge M, Munday R, Lenzen S (2000):
Relative importance of transport and alkylation for pancreatic beta-cell
toxicity of streptozotocin. Diabetologia. 43(12):1528-1533.
[6] Senanayake, G.V., Maruyama, M., Shibuya, K., Sakono, M., Fukuda,
(2004): The effects of bitter melon(Momordica charantia) on serum and
liver triglycride levels in rats. J. Ethnopharmacol.91(2-3):257-262.
[7] Trinder P (1969): Determination of blood glucose using an oxidaseperoxidase
system with a non-carcinogenic chromogen. J Clin Pathol
22(2): 158-161.
[8] Reitman S, Frankel S. (1957): A colorimetric method for the
determination of serum glutamic oxalacetic and glutamic pyruvic
transaminases. Am J Clin Pathol. 1957 Jul;28(1):56-63.
[9] Larsen K. (1972): Creatinine assay by a reaction-kinetic principle. Clin
Chim Acta. Oct;41:209-217.
[10] Naito H. K. (1984): High-density lipoprotein (HDL) cholesterol Kaplan.
A et al., clin chem. The c. v. Mosby co. st louis. Toronto. Princeton
1207-1213.
[11] Buccolo G et al., (1973): Quantitative determination of serum
triglycerides by use of enzymes. clin chem.. 19(5):476-482.
[12] Friedewald WT, Levy RI, Fredrickson DS (1972): Estimation of the
concentration of low-density lipoprotein cholesterol in plasma, without
use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
[13] Beutler E, Duron O, Kelly BM. (1963): Improved method for the
determination of blood glutathione. J Lab Clin Med. May;61:882.
[14] Giustarini D, Dalle-Donne I, Colombo R, Milzani A, Rossi R. (2004):
Adaptation of the Griess reaction for detection of nitrite in human
plasma. Free Radic Res. 38(11):1235-1240.
[15] Tatsuki R, Satoh K, Yamamoto A, Hoshi K, Ichihara K. (1997): Lipid
peroxidation in the pancreas and other organs in streptozotocin diabetic
rats. Jpn J Pharmacol. Nov;75(3):267-273.
[16] Sapin R, Le Galudec V, Gasser F, Pinget M, Grucker D. (2001): Elecsys
insulin assay: free insulin determination and the absence of Cross-
Reactivity with Insulin Lispro. Clinical Chemistry. 47:602-605.
[17] Verel D (1958): Simultaneous measurement of plasma volume with
dextran and Evans Blue: evidence for increased vascular permeability in
oedema and infection. Clin Sci (Lond) 17(4): 639-646.
[18] Chakir M, Plante GE, Maheux P. (1998): Reduction of capillary
permeability in the fructose-induced hypertensive rat. Am J Hypertens.
May;11(5):563-569.
[19] Whitby D. J., Ferguson M. W. J. (1991): Immunohistochemical
localization of growth factors in fetal wound healing, Dev. Biol. 147.
[20] SAS (2004): SAS user Guide:Statistics version,SAS Institute Inc, Cary,
NC-USA.
[21] Cobenas CJ, Spizzirri FD. Microalbuminuria in insulin-dependent
diabetes mellitus always indicative of diabetic nephropathy? Pediatr
Nephrol. 2003 Mar;18(3):309-310.
[22] Amini M, Parvaresh E. Prevalence of macro- and microvascular
complications among patients with type 2 diabetes in Iran: a systematic
review. Diabetes Res Clin Pract. 2009;83(1):18-25.
[23] Nerurkar PV, Lee YK, Motosue M, Adeli K and Nerurkar VR (2008):
Momordica charantia (bitter melon) reduces plasma apolipoprotein B-
100 and increases hepatic insulin receptor substrate and
phosphoinositide-3 kinase interactions. Br J Nutr 100(4): 751-759.
[24] Shih CC, Lin CH, Lin WL and Wu JB (2009): Momordica charantia
extract on insulin resistance and the skeletal muscle GLUT4 protein in
fructose-fed rats. J Ethnopharmacol 123(1): 82-90.
[25] Doi Y, Kubo M, Yonemoto K, Ninomiya T, Iwase M, Tanizaki Y, et al.,
(2007): Liver enzymes as a predictor for incident diabetes in a Japanese
population: the Hisayama study. Obesity 15(7): 1841-1850.
[26] Inoue K, Matsumoto M, Miyoshi Y and Kobayashi Y (2008): Elevated
liver enzymes in women with a family history of diabetes. Diabetes Res
Clin Pract 79(3): e4-7.
[27] Pepato MT, Magnani MR, Kettelhut IC and Brunetti IL (1999): Effect
of oral vanadyl sulfate treatment on serum enzymes and lipids of
streptozotocin-diabetic young rats. Mol Cell Biochem 198(1-2): 157-
161.
[28] Ezekwe MO and Martin RJ (1980): The effects of maternal alloxan
diabetes on body composition, liver enzymes and metabolism and serum
metabolites and hormones of fetal pigs. Horm Metab Res 12(4): 136-
139.
[29] Badria FA, Abou-Seif M, Osama M and Ahmed AF (2006): Evaluation
of the hypoglycemic effect and mechanism of action of Balanites
aegyptiaca on streptozotocin-induced diabetic rats. First International
Symposia about pharmacology of natural products and BLACPMA
Revista Cubana de Farmacia vol. 40.
[30] Martocchia A, Risicato MG, Mattioli C, Antonelli M, Ruco L and
Falaschi P (2008): Association of diffuse liver glycogenosis and mild
focal macrovesicular steatosis in a patient with poorly controlled type 1
diabetes. Intern Emerg Med 3(3): 273-274.
[31] Kwong,L,K.,Feingold,K.R.,PericGolia,L.,Le,le,T., Karkas, J.D., Alberts,
A.W. and Wilson, D.E.,(1991) :Intestinal and hepatic chlestrogenesis in
htperchlesterolemic dyslidemia of expermintal diabetetes in
dogs.Diabetes.40(12):1630-9.
[32] Chaturvedi P, George S, Milinganyo M and Tripathi YB (2004): Effect
of Momordica charantia on lipid profile and oral glucose tolerance in
diabetic rats. [33] Sharma RD, Raghuram TC and Rao NS (1990):
Effect of fenugreek seeds on blood glucose and serum lipids in type I
diabetes. Eur J Clin Nutr 44(4): 301-306. Phytother Res 18(11): 954-
956.
[33] Sharma RD, Raghuram TC and Rao NS (1990): Effect of fenugreek
seeds on blood glucose and serum lipids in type I diabetes. Eur J Clin
Nutr 44(4): 301-306.
[34] Iwasaki N, Ogata M, Tomonaga O, Kuroki H, Kasahara T, Yano N and
Iwamoto Y (1998): Liver and kidney function in Japanese patients with
maturity-onset diabetes of the young. Diabetes Care 21(12): 2144-2148.
[35] Guijarro C, Kasiske BL, Kim Y, O'Donnell MP, Lee HS and Keane WF
(1995): Early glomerular changes in rats with dietary-induced
hypercholesterolemia. Am J Kidney Dis 26(1): 152-161.
[36] Jafar TH, Schmid CH and Levey AS (2005): Serum creatinine as marker
of kidney function in South Asians: a study of reduced GFR in adults in
Pakistan. J Am Soc Nephrol 16(5): 1413-1419.
[37] Menini S, Iacobini C, Oddi G, Ricci C, Simonelli P, Fallucca S et al.,
(2007): Increased glomerular cell (podocyte) apoptosis in rats with
streptozotocin-induced diabetes mellitus: role in the development of
diabetic glomerular disease. Diabetologia 50(12): 2591-2599.
[38] Hamden K, Masmoudi H, Carreau S and Elfeki A (2010):
Immunomodulatory, beta-cell, and neuroprotective actions of fenugreek
oil from alloxan-induced diabetes. Immunopharmacol Immunotoxicol.
2010 Jan 25.
[39] Shetty AK, Kumar GS, Sambaiah K, Salimath PV (2005). Effect of
bitter gourd (Momordica charantia) on glycaemic status in
streptozotocin induced diabetic rats. Plant Foods Hum Nutr. 60(3):109-
12.
[40] Kakkar R, Kalra J, Mantha SV and Prasad K (1995): Lipid peroxidation
and activity of antioxidant enzymes in diabetic rats. Mol Cell Biochem
151(2): 113-119.
[41] Bhatia S, Shukla R, Venkata Madhu S, Kaur Gambhir J and Madhava
Prabhu K (2003): Antioxidant status, lipid peroxidation and nitric oxide
end products in patients of type 2 diabetes mellitus with nephropathy.
Clin Biochem 36(7): 557-562.
[42] Lapshina EA, Sudnikovich EJ, Maksimchik JZ, Zabrodskaya SV,
Zavodnik LB et al., (2006): Antioxidative enzyme and glutathione Stransferase
activities in diabetic rats exposed to long-term ASA
treatment. Life Sci 79(19): 1804-1811.
[43] Watanabe C, Kasanuma Y, Dejima Y and Satoh H (1999): The effect of
prenatal methylmercury exposure on the GSH level and lipid
peroxidation in the fetal brain and placenta of mice. Tohoku J Exp Med
187(2): 121-126.
[44] Colasanti M and Suzuki H (2000): The dual personality of NO. Trends
Pharmacol Sci 21(7): 249-252.
[45] Perreault M and Marette A (2001): Targeted disruption of inducible
nitric oxide synthase protects against obesity-linked insulin resistance in
muscle. Nat Med 7(10): 1138-1143.
[46] Maejima K, Nakano S, Himeno M, Tsuda S, Makiishi H, Ito T,
Nakagawa A et al., (2001): Increased basal levels of plasma nitric oxide
in Type 2 diabetic subjects. Relationship to microvascular
complications. J Diabetes Complications 15(3): 135-143.
[47] Behrendt D and Ganz P (2002): Endothelial function. From vascular
biology to clinical applications. Am J Cardiol 90 (10C): 48.
[48] Winterbourn CC. Free radical toxicology and antioxidant defence. Clin
Exp Pharmacol Physiol. 1995 Nov;22(11):877-880.
[49] Joshua IG, Zhang Q, Falcone JC, Bratcher AP, Rodriguez WE and
Tyagi SC (2005): Mechanisms of endothelial dysfunction with
development of type 1 diabetes mellitus: role of insulin and C-peptide. J
Cell Biochem 96(6): 1149-1156.
[50] de Jager J, Dekker JM, Kooy A, Kostense PJ, Nijpels G, Heine RJ,
Bouter LM and Stehouwer CDA (2006): Endothelial dysfunction and
low-grade inflammation explain much of the excess cardiovascular
mortality in individuals with type 2 diabetes: the Hoorn Study.
Arterioscler Thromb Vasc Biol 26(5): 1086-1093.
[51] Picchi A, Gao X, Belmadani S, Potter BJ, Focardi M, Chilian WM and
Zhang C (2006): Tumor necrosis factor-alpha induces endothelial
dysfunction in the prediabetic metabolic syndrome. Circ Res 99(1): 69-
77.
[52] Brausewetter F, Jehle PM, Jung MF, Boehm BO, Brueckel J, Hombach
V and Osterhues HH (2001): Microvascular permeability is increased in
both types of diabetes and correlates differentially with serum levels of
insulin-like growth factor I (IGF-I) and vascular endothelial growth
factor (VEGF). Horm Metab Res 33(12): 713-720.
[53] Gordon PA. (2004): Effects of diabetes on the vascular system: current
research evidence and best practice recommendations. J Vasc Nurs.
22(1):2-11.
[54] Hulthen UL, Rumble J, Cooper ME and Johnston CI (1995): Vascular
albumin permeability and hypertrophy in a rat model combining
streptozotocin-induced diabetes and genetic hypertension. J Hypertens
13(5): 529-533.
[55] Viberti GC (1983): Increased capillary permeability in diabetes mellitus
and its relationship to microvascular angiopathy. Am J Med 75(5B): 81-
84.
[56] Lawson SR, Gabra BH, Guerin B, Neugebauer W, Nantel F, Battistini B
and Sirois P (2005): Enhanced dermal and retinal vascular permeability
in streptozotocin-induced type 1 diabetes in Wistar rats: blockade with a
selective bradykinin B1 receptor antagonist. Regul Pept 124(1-3): 221-
224.
[57] Nakajima K, Morikawa A and Makino I (1994): Natural history of Bcell
dysfunction in spontaneously diabetic Chinese hamsters. Diabetes
Res Clin Pract 24(3): 131-142.
[58] Abaci A, Oguzhan A, Kahraman S, Eryol NK, Unal S, Arinc H and
Ergin A (1999): Effect of diabetes mellitus on formation of coronary
collateral vessels. Circulation 99(17): 2239-2242.
[59] Bild DE, Selby JV, Sinnock P, Browner WS, Braveman P and
Showstack JA (1989): Lower-extremity amputation in people with
diabetes. Epidemiology and prevention. Diabetes Care 12(1): 24-31.
[60] Pinzur MS, Slovenkai MP, Trepman E and Shields NN (2005):
Guidelines for diabetic foot care: recommendations endorsed by the
Diabetes Committee of the American Orthopaedic Foot and Ankle
Society. Foot Ankle Int 26(1): 113-119.
[61] Jeffcoate WJ, Price P, Harding KG (2004). International Working Group
on Wound Healing and Treatments for People with Diabetic Foot
Ulcers. Wound healing and treatments for people with diabetic foot
ulcer. Diabetes Metab Res Rev; 20: 878-89.
[62] Qiu Z, Kwon AH, Kamiyama Y (2006). Effects of plasma fibronectin
on the healing of full-thickness skin wounds in streptozotocin-induced
diabetic rats. J Surg Res; 138: 64-70.
[63] Kawanabe T, Kawakami T, Yatomi Y et al., (2007): Sphingosine 1-
phosphate accelerates wound healing in diabetic mice. J Dermatol Sci;
48: 53-60.
[64] Sardari K, Kakhki EG, Mohri M. (2007): Evaluation of wound
contraction and epithelialization after subcutaneous administration of
Theranekron- in cows. Comp Clin Pathol; 16: 197-200.
[65] Serarslan G, Altug E, Kontas T et al., (2007). Caffeic acid phenethyl
ester accelerates cutaneous wound healing in a rat model and decreases
oxidative stress. Clin Exp Dermatol; 32: 709-15.
[66] Szkudelski, T., (2001): The mechanism of alloxan and streptozotocin
action in beta cells of rat pancreas. Physiol. Res., 50, 536.